Submit Manuscript  

Article Details

PCSK9 inhibitors for the management of dyslipidemia in people with Type 2 Diabetes: How low is too low?


Ioannis Felekos, Grigoris V. Karamasis and Antonis N. Pavlidis*   Pages 1 - 8 ( 8 )


Diabetic patients are considered as high risk for development of atherosclerotic disease. Cholesterol treatment is of paramount importance in order to optimise cardiovascular outcomes in this subset of patients. Although statins are regarded as the mainstay of treatment, these may not be tolerated or as efficacious as they should be. Recently the advent of PCSK-9 inhibitors has drawn attention in the management of dyslipidemias. In this review we discuss current trends in their use and we focus in their role in diabetic dyslipidemia management.


PCSK9 inhibitors, dyslipidemia, diabetes.


Bristol Heart Institute, Bristol, Department of Cardiology, Essex Cardiothoracic Centre, Basildon, Cardiology Department, St. Thomas' Hospital, London

Read Full-Text article